Invesco Ltd. Invests $3.87 Million in NewAmsterdam Pharma (NASDAQ:NAMS)

Invesco Ltd. acquired a new stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 150,559 shares of the company's stock, valued at approximately $3,869,000. Invesco Ltd. owned about 0.16% of NewAmsterdam Pharma as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Jennison Associates LLC boosted its stake in shares of NewAmsterdam Pharma by 291.9% during the 4th quarter. Jennison Associates LLC now owns 3,998,541 shares of the company's stock worth $102,763,000 after purchasing an additional 2,978,263 shares during the last quarter. Wellington Management Group LLP grew its stake in NewAmsterdam Pharma by 2,410.4% in the 4th quarter. Wellington Management Group LLP now owns 2,315,123 shares of the company's stock worth $59,499,000 after acquiring an additional 2,222,900 shares during the period. Alliancebernstein L.P. acquired a new position in NewAmsterdam Pharma in the 4th quarter valued at $47,752,000. Pictet Asset Management Holding SA lifted its stake in shares of NewAmsterdam Pharma by 13.8% during the 4th quarter. Pictet Asset Management Holding SA now owns 1,157,452 shares of the company's stock worth $29,747,000 after purchasing an additional 140,605 shares during the period. Finally, TimesSquare Capital Management LLC boosted its holdings in shares of NewAmsterdam Pharma by 250.9% during the fourth quarter. TimesSquare Capital Management LLC now owns 895,574 shares of the company's stock worth $23,016,000 after purchasing an additional 640,329 shares during the last quarter. Hedge funds and other institutional investors own 89.89% of the company's stock.

NewAmsterdam Pharma Stock Up 0.3 %

NewAmsterdam Pharma stock opened at $17.52 on Monday. The firm has a market capitalization of $1.92 billion, a P/E ratio of -6.74 and a beta of -0.01. The firm has a fifty day moving average of $19.61 and a 200-day moving average of $21.24. NewAmsterdam Pharma has a 52-week low of $14.06 and a 52-week high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The business had revenue of $12.77 million during the quarter, compared to the consensus estimate of $3.30 million. On average, research analysts expect that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

Insider Buying and Selling

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 150,000 shares of the company's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total value of $3,055,500.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,000 shares of the company's stock, valued at $305,550. This represents a 90.91 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director James N. Topper bought 1,135 shares of the stock in a transaction dated Wednesday, March 26th. The shares were acquired at an average price of $22.49 per share, with a total value of $25,526.15. Following the completion of the purchase, the director now directly owns 3,013,569 shares of the company's stock, valued at approximately $67,775,166.81. This represents a 0.04 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 19.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on NAMS. Scotiabank increased their target price on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research report on Thursday, February 27th. HC Wainwright reissued a "buy" rating and issued a $48.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $40.00 price target on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. UBS Group set a $41.00 price target on shares of NewAmsterdam Pharma in a research note on Monday, March 3rd. Finally, Needham & Company LLC restated a "buy" rating and set a $42.00 price objective on shares of NewAmsterdam Pharma in a report on Tuesday, April 8th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $43.33.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.